Shutaishen’s STSP-0601 for injection obtains drug production license
May 16, 2025
Source: drugdu
172
On May 13, Shutaishen, an announcement was issued that the company's subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. (hereinafter referred to as "Beijietai") recently obtained a drug production license issued by the Jiangsu Provincial Food and Drug Administration.
The announcement stated that Beijietai has obtained the "Drug Production License" and will be commissioned to produce therapeutic biological products.(STSP-0601 for injection is limited to registration and application use) and is not expected to have a significant impact on the company's current performance. The relevant products can only be commercially produced after obtaining the drug marketing approval number.
https://finance.eastmoney.com/a/202505143404500613.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
- LH-1801 project enters Phase III clinical trial July 7, 2025
- The new generation of DNA biosynthesis technology is moving towards industrialization July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
